Search Result

32 results found
  • ASX Full Year Result 2014 Financial Statements

    CSL Limited ABN: 99 051 588 348 Annual Financial Report for the year ended 30 June 2014 CSL Limited Consolidated Statement of Comprehensive Income For the Year Ended 30 June 2014

  • ASX Half-year Information 31 December 2016

    588 348 ASX Half-year Information 31 December 2016 Lodged with the ASX under Listing Rule 4.2A. This information should be read in conjunction with the 30 June 2016 Annual Report.

  • ASX Half-year Information 2015

    588 348 ASX Half-year Information 31 December 2015 Lodged with the ASX under Listing Rule 4.2A. This information should be read in conjunction with the 30 June 2015 Annual Report.

  • ASX Half-year Information 31 December 2012

    588 348 ASX Half-year Information 31 December 2012 Lodged with the ASX under Listing Rule 4.2A. This information should be read in conjunction with the 30 June 2012 Annual Report.

  • v080904

    588 348 ASX Half-year Information 31 December 2017 Lodged with the ASX under Listing Rule 4.2A. This information should be read in conjunction with the 30 June 2017 Annual Report.

  • Chairmans Address AGM 2015

    30 June 2015. I hope that you have taken the opportunity to read our most recent Annual Report. "I am very pleased to report that CSL recorded another year of solid business

  • Chairmans Address AGM 2016

    Opportunity to read our most recent Annual Report. "I am very pleased to report that CSL delivered another strong performance with double digit growth in all plasma therapy groups.

  • Financial Results and Information | CSL Limited

    CSL's exceptionally strong performance is a result of the focused execution of our strategy. Learn more.

  • Chairman's Address AGM 2017

    30 June 2017. I hope that you have taken the opportunity to read our most recent Annual Report, copies of which are available here and also on CSL's website. "I am very pleased

  • CSL Limited is a global biotherapy industry leader.

    CSL Limited is a global biotechnology manufacturer that researches, develops, and markets products to treat and prevent rare and serious diseases. Learn more.